Nurix
A Scientist at Nurix Therapeutics conducts analytical method development and material characterization studies to inform drug substance and drug product development. They provide operational oversight at external CDMO/CTL partners, manage reference standards and impurity markers, collaborate in CMC risk management, and author technical reports.
Headquarters
Brisbane, California, United States
Company Size
201-500 employees
Founded
2012
Nurix Therapeutics is a clinical-stage biopharmaceutical company developing medicines that harness targeted protein degradation to treat cancer and autoimmune diseases. Using a proprietary platform that combines small-molecule degraders and Degradation Activating Compounds (DACs) to engage E3 ubiquitin ligases and the ubiquitin–proteasome system, Nurix aims to selectively remove disease-causing proteins. The company advances multiple discovery and development programs and collaborates with partners to translate its platform into novel therapies. Their mission, "Medicines to Outmatch Disease," guides efforts to create differentiated, targeted treatments.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Nurix.
59% above the average for this role
Nurix Therapeutics: Why This Company Could Double In Value? (NASDAQ:NRIX)
1 month ago
Principal Scientist, Analytical Development
Bristol Myers Squibb
Scientist II, Analytical Development
PepGen
Executive - Analytical Development
Sun Pharmaceutical Industries Limited
Director, Synthetic Molecules Analytical R&D
AbbVie
Scientist
Pace® Analytical Services
Post Doc, Formulations and Analytical Chemistry
Radware